Norbert Frickhofen

Helios Dr. Horst Schmidt Kliniken Wiesbaden — Germany

Medicine · Health Sciences

40h-index7.1kcitations161works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(25), Lung Cancer Treatments and Mutations(21), Acute Myeloid Leukemia Research(20), Hematopoietic Stem Cell Transplantation(18), Parvovirus B19 Infection Studies(18)

Publications161 total

157 | PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL > 60 TRIAL OF THE DSHNHL/GLA
Hematological Oncology·2025Open Access
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
HemaSphere·2023· 14 citedOpen Access
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
HemaSphere·2023· 14 citedOpen Access
Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Blood·2022· 16 citedOpen Access
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial
Oncology Research and Treatment·2021· 2 citedOpen Access
Differential impact of <i>IDH1</i>/<i>2</i> mutational subclasses on outcome in adult AML: results from a large multicenter study
Blood Advances·2021· 41 citedOpen Access
Impact of <i>PTPN11</i> mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
Blood Advances·2021· 34 citedOpen Access
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
HemaSphere·2021· 4 citedOpen Access
Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
Cancers·2021· 10 citedOpen Access
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
Leukemia·2021· 57 citedOpen Access
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ method
European Journal of Cancer·2021· 29 cited
Tumorbiologie für Nichtonkologen
Elsevier eBooks·2021
Adressen
Elsevier eBooks·2021
67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
Annals of Oncology·2020· 4 citedOpen Access
Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227
Cancer Research·2020· 28 cited
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?
Blood·2020· 133 citedOpen Access
Implementing a novel method to estimate the "Burden of Therapy" (BOTh) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib vs. gemcitabine in the AIO ACCEPT trial.
Journal of Clinical Oncology·2020
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry
Journal of Cancer Research and Clinical Oncology·2020· 129 citedOpen Access
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
The Lancet·2019· 244 citedOpen Access
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia
Blood·2019· 18 cited
page 1 of 9Next →

Frequent Co-authors

Hermann Einsele(9), Hubert Serve(8), Andreas Neubauer(8), Stefan W. Krause(8), Mathias Hänel(8), Christoph Röllig(7), Richard Noppeney(7), Carsten Müller‐Tidow(7), Claudia D. Baldus(7), Ulrich Kaiser(7), Christian Thiede(7), Wolfgang E. Berdel(7), Gerhard Ehninger(7), Volker Kunzmann(6), Kerstin Schäfer‐Eckart(6), Martin Bornhäuser(6), Markus Schaich(6), Johannes Schetelig(6), Michael Krämer(6), Alwin Krämer(5)